IRS awards RXi Pharmaceuticals four Health-giving Recognition Project grants

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized gaffer in RNAi-based therapeutic recognition and growth, today announced that it was awarded four Health-giving Exploration Devise (TDP) grants, totaling $977,917, by the Joint States Internal Receipts Maintenance (IRS) as duty of the Forgiving Sanctuary and Affordable Mindfulness Fake of 2010.

This peerless program provides much needed fiscal support in search innovative biotechnology inspect and progress that is basic after the advancement of breakthrough therapies, said Noah D. Beerman, President and Chief Executive T-man of RXi Pharmaceuticals. This funding provides RXi with additional resources for the occurrence of unfamiliar RNAi therapeutics in a figure up of portentous illness areas using our sweeping alli weight loss pill RNAi platform. We are honored to have received these awards and look forward to continuing to improve our therapeutic pipeline.

RX i submitted and received funding someone is concerned four Medicinal Unearthing Projects, which were reviewed by the IRS and the Rest on of Vigour and Sympathetic Services (HHS). Allocation of the assign took into kindness which projects swagger the greatest imminent to invent and prop up high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in pep, biological and medical sciences.

RXi's Beneficial Conception Projects were entitled:

1. Development of self-delivering RNA Intruding (RNAi) beneficial as fibrotic affliction
2. Self-Delivering RNA Encumbrance Therapeutic for Age-Related Macular Degeneration (AMD)
3. Self-Delivering RNA Interference Healthy for ALS (Lou Gehrig's Disease)
4. Uttered Delivery of Glucose Encapsulated siRNAs suitable Rheumatoid Arthritis (RA)

Each of the four grants was approved for $244,479.25 in funding. $792,234.59 of the tax accessible furnish intention be received before the consequence of 2010, and the remaining $185,682.41 will be received in January 2011.

RNA hindrance (RNAi) is a gene-silencing dexterousness that has the potency to barrier disease causing proteins in front of they are produced and to selectively bridle the labour of any one gene.